Moffitt Cancer Center Aug 12, 2021 Florida Researchers Net $3.95M NIH Grant to Study Genomics of Uveal Melanoma Metastasis Jul 15, 2021 Puma Biotechnology Provides $1.4M to NCCN-Chosen Studies of Nerlynx in Gastric Cancers Feb 5, 2021 With First-In-Class Iovance BLA Pending, TIL Therapies on Cusp of Commercialization Premium Jan 12, 2021 Moffitt Cancer Center, Exuma Biotech Partner to Advance Point-of-Care CAR T-cell Therapy Program Dec 10, 2020 Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression Apr 7, 2020 Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction Premium Mar 24, 2020 Precision Oncology Programs Adapting to Ensure Patient Safety, Care During Public Health Crisis Feb 25, 2020 Oncologie, Moffitt Collaborate to Develop Targeted Treatment for Gastric, GI Cancers Nov 22, 2019 Racial Group Comparison Suggests More Research Needed on Prostate Cancer Recurrence Tests Premium Sep 17, 2019 Cancer Centers Investing in Research Autopsies to Explore Why Patients Fail Precision Medicine Premium Aug 13, 2019 Squamous Cell Lung Cancer Subtypes Point to Potential Therapeutic Approaches Premium Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
